Volume 27, Issue 3 (September 2023)                   Physiol Pharmacol 2023, 27(3): 271-282 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Seiiedy M, Salehi C, Ghasemnejad Berengi M, karimipour M, Rezaie J, Babataheri S et al . Cardioprotective effects of Ganoderma lucidum on isoproterenol–induced heart failure. Physiol Pharmacol 2023; 27 (3) :271-282
URL: http://ppj.phypha.ir/article-1-2001-en.html
Abstract:   (976 Views)

Introduction: Ganoderma lucidum (G. lucidum), a medicinal mushroom, exerts protective effects on cardiovascular diseases but, it’s effect in isoproterenol-induced heart failure has not been studied. Therefore, the aim of the present study was whether G. lucidum has protective effects in isoproterenol-induced heart failure.
Methods: Thirty male Wistar rats were assigned into five groups (n=6) of control, heart failure (HF) and G. lucidum (50, 100 and 200mg/kg). For induction of HF in rats, isoproterenol (5mg/ kg) was injected subcutaneously for two weeks. In G. lucidum treated groups, G. lucidum was orally gavaged for three weeks and on day 8 isoproterenol was injected for two weeks. Then, Electrocardiogram pattern and cardiodynamic parameters, as well as myeloperoxidase activity, malondialdehyde level, cardiac remodeling and apoptosis were studied.
Results: G. lucidum improved hemodynamic factors such as mean arterial blood pressure as well as electrocardiogram pattern. Pre-treatment with G. lucidum also decreased myeloperoxidase activity, malondialdehyde level and apoptosis in cardiac tissue. Histopathologic results showed a decrease in cardiac necrosis and fibrosis. However, it had no significant effect on cardiac hypertrophy.
Conclusion: Our results show that pre-treatment with G. lucidum demonstrates protective effects against HF, and thereby suggest that G. lucidum can be considered as a possible clinical use for preventive and adjuvant treatment in heart failure.

Full-Text [PDF 2886 kb]   (317 Downloads)    

1. Abbaszadeh S, Javidmehr A, Askari B, Janssen PML, Soraya H. Memantine, an NMDA receptor antagonist, attenuates cardiac remodeling, lipid peroxidation and neutrophil recruitment in heart failure: A cardioprotective agent?. Biomed Pharmacother 2018; 108:1237-1243. [DOI:10.1016/j.biopha.2018.09.153]
2. Akihisa T, Nakamura Y, Tagata M, Tokuda H, Yasukawa K, Uchiyama E, et al. Anti-inflammatory and anti-tumor-promoting effects of triterpene acids and sterols from the fungus Ganoderma lucidum. Chem Biodivers 2007; 4:224-231. [DOI:10.1002/cbdv.200790027]
3. Anzai T. Post-infarction inflammation and left ventricular remodeling: a double-edged sword. Circ J 2013; 77:580-587. [DOI:10.1253/circj.cj-13-0013]
4. Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT, Clark WA. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res 1989; 65:657-670. [DOI:10.1161/01.res.65.3.657]
5. Bishop KS, Kao CH, Xu Y, Glucina MP, Paterson RRM, Ferguson LR. From 2000 years of Ganoderma lucidum to recent developments in nutraceuticals. Phytochemistry 2015; 114:56-65. [DOI:10.1016/j.phytochem.2015.02.015]
6. Chen HS, Tsai YF, Lin S, Lin CC, Khoo KH, Lin CH, et al. Studies on the immuno-modulating and anti-tumor activities of Ganodermalucidum (Reishi) polysaccharides. Bioorg Med Chem 2004; 12:5595-5601. [DOI:10.1016/j.bmc.2004.08.003]
7. Chen J, Shi Y, He L, Hao H, Wang B, Zheng Y, et al. Protective roles of polysaccharides from Ganoderma lucidum on bleomycin-induced pulmonary fibrosis in rats. Int J Biol Macromol 2016; 92:278-281. [DOI:10.1016/j.ijbiomac.2016.07.005]
8. Costa S, Reina-Couto M, Albino-Teixeira A, Sousa . Statins and oxidative stress in chronic heart failure. Rev Port Cardiol 2016; 35:41-57. [DOI:10.1016/j.repc.2015.09.006]
9. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005; 115:500-508. [DOI:10.1172/JCI24408]
10. Hsu MJ, Lee SS, Lin WW. Polysaccharide purified from Ganoderma lucidum inhibits spontaneous and Fas-mediated apoptosis in human neutrophils through activation of the phosphatidylinositol 3 kinase/Akt signaling pathway. J Leukoc Biol 2002; 72:207-216. [DOI:10.1189/jlb.72.1.207]
11. Ikeguchi M, Hirooka Y, Kaibara N. Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma. Cancer 2002; 95:1938-1945. [DOI:10.1002/cncr.10898]
12. Jannesar K, Abbaszadeh S, Malekinejad H, Soraya H. Cardioprotective effects of memantine in myocardial ischemia: Ex vivo and in vivo studies. Eur J Pharmacol 2020; 882:173277. [DOI:10.1016/j.ejphar.2020.173277]
13. Jefferson BK, Topol EJ. Molecular mechanisms of myocardial infarction. Curr Probl Cardiol 2005; 30:333-374. [DOI:10.1016/j.cpcardiol.2005.02.002]
14. Johnson FL. Pathophysiology and etiology of heart failure. Cardiol Clin 2014; 32:9-19. [DOI:10.1016/j.ccl.2013.09.015]
15. Kabir Y, Kimura S, Tamura T. Dietary effect of Ganoderma lucidum mushroom on blood pressure and lipid levels in spontaneously hypertensive rats (SHR). J Nutr Sci Vitaminol 1988; 34:433-438. [DOI:10.3177/jnsv.34.433]
16. Karagöz A, Kesici S, Vural A, Usta M, Tezcan B, Semerci T, et al. Cardioprotective effects of Viscum album L. ssp. album (Loranthaceae) on isoproterenol-induced heart failure via regulation of the nitric oxide pathway in rats. Anatol J Cardiol 2016; 16:923-930. [DOI:10.14744/AnatolJCardiol.2016.6780]
17. Kim NH, Kang PM. Apoptosis in cardiovascular diseases: mechanism and clinical implications. Korean Circ J 2010; 40:299-305. [DOI:10.4070/kcj.2010.40.7.299]
18. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 2011;4: 98-108. [DOI:10.1016/j.jcmg.2010.10.008]
19. Lasukova TV, Arbuzov AG, Maslov LN, Burkova VN. Ganoderma lucidum extract in cardiac diastolic dysfunction and irreversible cardiomyocytic damage in ischemia and reperfusion of the isolated heart. Patol Fiziol Eksp Ter 2008; (1):22-25.
20. Lasukova TV, Maslov LN, Arbuzov AG, Burkova VN, Inisheva LI. Cardioprotective activity of Ganoderma lucidum extract during total ischemia and reperfusion of isolated heart. Bull Exp Biol Med 2015; 158:739-741. [DOI:10.1007/s10517-015-2851-7]
21. Li F, Zhang Y, Zhong Z. Antihyperglycemic effect of Ganoderma lucidum polysaccharides on streptozotocin-induced diabetic mice. Int J Mol Sci 2011; 12:6135-6145. [DOI:10.3390/ijms12096135]
22. Li WJ, Li L, Zhen WY, Wang LF, Pan M, Lv JQ, et al. Ganoderma atrum polysaccharide ameliorates ROS generation and apoptosis in spleen and thymus of immunosuppressed mice. Food Chem Toxicol 2017; 99:199-208. [DOI:10.1016/j.fct.2016.11.033]
23. Lin ZB, Zhang HN. Anti-tumor and immunoregulatory activities of Ganoderma lucidum and its possible mechanisms. Acta Pharmacol Sin 2004; 25: 1387-1395.
24. Loria V, Dato I, Graziani F, Biasucci LM. Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators inflamm 2008; 2008:135625. [DOI:10.1155/2008/135625]
25. Ma T, Zhu D, Chen D, Zhang Q, Dong H, Wu W, et al. Sulforaphane, a natural isothiocyanate compound, improves cardiac function and remodeling by inhibiting oxidative stress and inflammation in a rabbit model of chronic heart failure. Med Sci Monit 2018; 24:1473-1483. [DOI:10.12659/msm.906123]
26. Meng J, Yang B, Protective Effect of Ganoderma (Lingzhi) on Cardiovascular System. Adv Exp Med Biol 2019; 1182:181-199. [DOI:10.1007/978-981-32-9421-9_7]
27. Mullane KM, Kraemer R, Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemie myocardium. J Pharmacol Methods 1985; 14:157-67. [DOI:10.1016/0160-5402(85)90029-4]
28. Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H, Nakamura T. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 2000; 106:1511-1519. [DOI:10.1172/JCI10226]
29. Qiao J, Dou Z, Wu F, Meng G, Chen H, Zhen H, Effects of Ganoderma lucidum polysaccharides combined with metformin on myocardial structure and hemodynamics in type 2 diabetic rats. Chinese Pharmacol. Bull 2016; 32:1012-1016. [DOI:10.3969/j.issn.1001-1978.2016.07.024]
30. Rameshrad M, Soraya H, Maleki-Dizaji N, Vaez H, Garjani A. A-769662, a direct AMPK activator, attenuates lipopolysaccharide-induced acute heart and lung inflammation in rats. Mol Med Rep 2016; 13:2843-2849. [DOI:10.3892/mmr.2016.4821]
31. Sargowo D, Ubaidillah N, Handayani O, Widya A, Vittryaturida V, Siwi K, et al. PS 02-02 Effect Ganoderma lucidum polysaccharide peptides as anti-hypertension, anti-lipid, anti-oxidant, anti-inflammation in high risk patients of atherosclerosis. J. Hypertens 2016; 34: e105. [DOI:10.1097/01.hjh.0000500132.15515.a3]
32. Sedmera D, Neckar J, Benes J Jr, Pospisilova J, Petrak J, Sedlacek K, et al. Changes in myocardial composition and conduction properties in rat heart failure model induced by chronic volume overload. Front Physiol 2016; 7:367. [DOI:10.3389/fphys.2016.00367]
33. Senoner T, Dicht W. Oxidative stress in cardiovascular diseases: still a therapeutic target? Nutrients 2019; 11: E2090. [DOI:10.3390/nu11092090]
34. Sinha N, Dabla PK. Oxidative stress and antioxidants in hypertension–a current review. Curr Hypertens Rev 2015; 11:132-142. [DOI:10.2174/1573402111666150529130922]
35. Siwulski M, Sobieralski K, Golak-Siwulska I, Sokół S, Sękara A. Ganoderma lucidum (Curt.: Fr.) Karst.–health-promoting properties. Herba Polonica 2015; 61:105-118. [DOI:10.1515/hepo-2015-0026]
36. Soraya H, Khorrami A, Garjani A, Maleki-Dizaji N, Garjani A. Acute treatment with metformin improves cardiac function following isoproterenol induced myocardial infarction in rats. Pharmacol Rep 2012; 64:1476-1484. [DOI:10.1016/s1734-1140(12)70945-3]
37. Sun XZ, Liao Y, Li W, Guo LM. Neuroprotective effects of Ganoderma lucidum polysaccharides against oxidative stress-induced neuronal apoptosis. Neural Regen Res 2017; 12:953-958. [DOI:10.4103/1673-5374.208590]
38. Susilo RJK, Winarni D, Husen SA, Hayaza S, Punnapayak H, Wahyuningsih SPA, et al. Hepatoprotective effect of crude polysaccharides extracted from Ganoderma lucidum against carbon tetrachloride-induced liver injury in mice. Vet World 2019; 12:1987-1991. [DOI:10.14202/vetworld.2019.1987-1991]
39. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol 2011; 301:H2181-190. [DOI:10.1152/ajpheart.00554.2011]
40. Veena RK, Ajith TA, Janardhanan KK. Lingzhi or Reishi medicinal mushroom, Ganoderma lucidum (Agaricomycetes), prevents doxorubicin-induced cardiotoxicity in rats. Int J Med Mushrooms 2018; 20:761-774. [DOI:10.1615/IntJMedMushrooms.2018027010]
41. Wachtel-Galor S, Tomlinson B, Benzie IF. Ganoderma lucidum (‘Lingzhi’), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study. Br J Nutr 2004; 91:263-269. [DOI:10.1079/BJN20041039]
42. Waty IS, Wihastuti TA, WidodoMA SargowoD. Effect of polysaccharide peptide (Ganodermalucidum) against inflammatory processes focused on IL-6 and hsCRPin atherosclerosis. J. Hypertens 2015; 33: e38. [DOI:10.1097/01.hjh.0000469863.77306.a9]
43. Wong KL, Chao HH, Chan P, Chang LP, Liu CF. Antioxidant activity of Ganoderma lucidum in acute ethanol-induced heart toxicity. Phytother Res 2004; 18:1024-1026. [DOI:10.1002/ptr.1557]
44. Xie YZ, Yang F, Tan W, Li X, Jiao C, Huang R, et al. The anti-cancer components of Ganoderma lucidum possesses cardiovascular protective effect by regulating circular RNA expression. Oncoscience 2016; 3:203-207. [DOI:10.18632/oncoscience.316]
45. Xue H, Qiao J, Meng G, Wu F, Luo J, Chen H, et al. Effect of Ganoderma lucidum polysaccharides on hemodynamic and antioxidation in T2DM rats. Zhongguo Zhong Yao Za Zhi 2010; 35:339-343. [DOI:10.4268/cjcmm20100318]
46. Xu F, Li X, Xiao X, Liu LF, Zhang L, Lin PP, et al. Effects of Ganoderma lucidum polysaccharides against doxorubicin-induced cardiotoxicity. Biomed Pharmacother 2017; 95:504-512. [DOI:10.1016/j.biopha.2017.08.118]
47. Young IS, Trimble ER. Measurement of malondialdehyde in plasma by high performance liquid chromatography with fluorimetric detection. Ann Clin Biochem 1991; 28:504-508. [DOI:10.1177/000456329102800514]
48. Zeng P, Guo Z, Zeng X, Hao C, Zhang Y, Zhang M, et al. Chemical, biochemical, preclinical and clinical studies of Ganoderma lucidum polysaccharide as an approved drug for treating myopathy and other diseases in China. J Cell Mol Med 2018; 22:3278-3297. [DOI:10.1111/jcmm.13613]
49. Zhang W, Zhang Q, Deng W, Li Y, Xing G, Shi X, et al. Neuroprotective effect of pretreatment with Ganoderma lucidum in cerebral ischemia/reperfusion injury in rat hippocampus. Neural Regen Res 2014; 9:1446-1452. [DOI:10.4103/1673-5374.139461]
50. Zhao W, Jiang X, Deng W, Lai Y, Wu M, Zhang Z. Antioxidant activities of Ganoderma lucidum polysaccharides and their role on DNA damage in mice induced by cobalt-60 gamma-irradiation. Food Chem Toxicol 2012; 50:303-309. [DOI:10.1016/j.fct.2011.10.071]

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.